DPP4 and type 2 diabetes mellitus: However, a retrospective cohort study using data from the Clinical Practice Research Datalink (CPRD) in the UK, previously known as the General Practice Research Database (GPRD) [https://www.cprd.com] (accessed on 25 May 2021), showed that DPP-4 inhibitor use among patients with type 2 diabetes was not associated with differences in fracture risk compared to nondiabetic controls or to patients receiving other adjusting for use of other antidiabetic drugs, such as metformin, sulfonylurea (SU), and thiazolidinedione (TZD) [146].